MedTrace Logo

Suvorexant for Opioid/Stimulant Co-use

NCT05546515 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-12-23

Study results available
· View outcomes & findings →

Summary

This study will evaluate whether Suvorexant 20mg reduces drug use and craving, and improves sleep and stress among persons with co-occurring opioid use disorder and stimulant use disorder.

Conditions

Interventions

DRUG

Suvorexant (dual orexin receptor antagonist)

Participants will be prescribed up to 30 days of SUVO.

DRUG

Placebo

Participants will be prescribed up to 30 days of placebo medication.

Sponsors & Collaborators

Principal Investigators

  • Jennifer Ellis, Ph.D. · Johns Hopkins School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2024-11-30
Completion
2024-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05546515 on ClinicalTrials.gov